

# 6. BÖLÜM

## Esrar

Ahmet ULUGÖL<sup>1</sup>  
Serap Annette AKGÜR<sup>2</sup>

Esrar, kenevir (kannabis) bitkisinden elde edilen maddenin halk arasında yasadışı kullanımının adı olup, ABD’de marihuana ismiyle bilinir. Çok yaygın bir şekilde keyif verici olarak kullanılmasının yanı sıra son senelerde tıbbi kullanımı yeniden ön plana çıkmaya başlamıştır. Medikal kannabis denildiğinde, hekimlerin tedavi için önerdikleri bitkisel ve diğer kannabinoid ilaçlar anlaşılır. Kannabinoidler kendi reseptörlerini (CB<sub>1</sub> ve CB<sub>2</sub>) uyararak etkinliklerini ortaya çıkaran kimyasal maddeler olup, bitkisel kannabinoidler (kenevir bitkisinde bulunan doğal kannabinoidler, fitokannabinoidler), sentetik kannabinoidler ve vücudumuzda endojen olarak bulunan endokannabinoidlerin genel ismidir. “Sentetik kannabinoidler” ayrı bölüm olarak anlatılmaları nedeniyle bu bölüm içinde verilmeyeceklerdir.

### Genel Bilgi, Kısa Tarihçe ve Güncel Klinik/Yasal Durumu

Kannabis bitkisi, tropik ve ılıman bölgelerde yaygın olarak bulunan, Cannabaceae familyasına ait yıllık çiçekli bir bitki olup, türleri ve alt-türleri halen tartışmalıdır. *Cannabis sativa*, *Cannabis indica* ve *Cannabis ruderalis* bilinen alt-türlerdir; *Cannabis ruderalis* genellikle *Cannabis sativa*’nın alt-türü olarak kabul edilir. *Cannabis sativa* tüm iklimlerde kolaylıkla yetişebilirken *Cannabis*

<sup>1</sup> Prof. Dr. Trakya Üniversitesi Tıp Fakültesi Tıbbi Farmakoloji AD, aulugol@trakya.edu.tr

<sup>2</sup> Prof. Dr. Ege Üniversitesi, Madde Bağımlılığı, Toksikoloji ve İlaç Bilimleri Enstitüsü, Bağımlılık Toksikolojisi AD, serap.akgur@ege.edu.tr

## KAYNAKLAR

1. ElSohly M, Gul W. Constituents of Cannabis Sativa. In: *Pertwee RG (ed.) Handbook of Cannabis*. 1st ed. Oxford: Oxford University Press; 2014. p. 3–22.
2. Hillig KW. Genetic evidence for speciation in Cannabis (Cannabaceae). *Genetic Resources and Crop Evolution*. 2005;52(2): 161–180. doi:10.1007/s10722-003-4452-y
3. Russo E. The Pharmacological History of Cannabis. In: *Pertwee RG (ed.) Handbook of Cannabis*. 1st ed. Oxford: Oxford University Press; 2014. p. 23–43.
4. Crocq MA. History of cannabis and the endocannabinoid system. *Dialogues in Clinical Neuroscience*. 2020;22(3): 223–228. doi:10.31887/DCNS.2020.22.3/MCROCQ
5. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. *J Am Chem Soc*. 1960;86: 1646–1647.
6. Pisanti S, Bifulco M. Modern History of Medical Cannabis: From Widespread Use to Prohibitionism and Back. *Trends in Pharmacological Sciences*. Elsevier Ltd; 2017;38(3): 195–198. doi:10.1016/j.tips.2016.12.002
7. Ulugöl A. Kannabis Bitkisi ve Kannabinoidlere Giriş. *Turkiye Klinikleri J Pharmacol-Special Topics*. 2018;6(1): 1–5.
8. Akgür SA, Aydoğdu M. Cannabis Use in Turkey. *Turkiye Klinikleri J Pharmacol-Special Topics*. 2018;6(1): 57–61.
9. Alharbi YN. Current legal status of medical marijuana and cannabidiol in the United States. *Epilepsy and Behavior*. 2020;112: 107452. doi:10.1016/j.yebeh.2020.107452
10. Topuz RD. Kannabinoidlerin farmakolojisi. *PTurkiye Klinikleri J Pharmacol-Special Topics*. 2018;6(1): 6–14.
11. Grotenhermen F. Pharmacokinetics and the pharmacodynamics of cannabinoids. *Clin Pharmacokinet*. 2003;42(4): 327–360. doi:10.1111/bcp.13710
12. Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: A systematic review. *Drug Metabolism Reviews*. 2014;46(1): 86–95. doi:10.3109/03602532.2013.849268
13. Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. *British Journal of Clinical Pharmacology*. 2018;84(11): 2477–2482. doi:10.1111/bcp.13710
14. Pertwee RG. Pharmacological and therapeutic targets for  $\Delta^9$ -tetrahydrocannabinol and cannabidiol. *Euphytica*. 2004;140(1–2): 73–82. doi:10.1007/s10681-004-4756-9
15. Pertwee R. Receptors and Channels Targeted by Synthetic Cannabinoid Receptor Agonists and Antagonists. *Current Medicinal Chemistry*. 2010;17(14): 1360–1381. doi:10.2174/092986710790980050
16. Amin R, Ali D. Pharmacology of medical cannabis. *Adv Exp Med Biol*. 2019;1162: 151–165.
17. Gündüz Ö. Endokannabinoid sistem. *Turkiye Klinikleri J Pharmacol-Special Topics*. 2018;6(1): 15–24.
18. Russo EB. Beyond Cannabis: Plants and the Endocannabinoid System. *Trends in Pharmacological Sciences*. 2016;37(7): 594–605. doi:10.1016/j.tips.2016.04.005
19. Ulugöl A. The endocannabinoid system as a potential therapeutic target for pain modulation. *Balkan Medical Journal*. 2014;31(2): 115–120. doi:10.5152/balkanmedj.2014.13103
20. Topuz RD, Gündüz Ö, Karadağ ÇH, et al. Non-opioid Analgesics and the Endocannabinoid System. *Balkan Medical Journal*. 2020;37(6): 309–315. doi:10.4274/balkanmedj.galenos.2020.2020.6.66
21. Ashton CH. Pharmacology and effects of cannabis: A brief review. *British Journal of Psychiatry*. 2001;178(FEB.): 101–106. doi:10.1192/bjp.178.2.101
22. Hall W, Degenhardt L, Lynskey M. *The health and psychological effects of cannabis use*. 2nd ed. Canberra: University of New South Wales; 2001.
23. Karch S. *Pharmacokinetics and Pharmacodynamics of abused Drugs*. CRC press; 2008.

24. Hart CL, Ward AS, Haney M, et al. Comparison of smoked marijuana and oral  $\Delta^9$ -tetrahydrocannabinol in humans. *Psychopharmacology*. 2002;164(4): 407–415. doi:10.1007/s00213-002-1231-y
25. Akgür SA. Esrar ve Kannabinoidler. In: Akgür SA, Coşkunol H (eds.) *Bağımlılık Yapıcı Maddeler ve Toksikolojisi*. Ege Üniversitesi Madde Bağımlılığı, Toksikoloji ve İlaç Bilimleri Enstitüsü Yayınları No:3; 2014. p. 93–107.
26. Notcutt W, Clarke E. Cannabinoids in Clinical Practice: A UK Perspective. In: *Pertwee RG (ed.) Handbook of Cannabis*. 1st ed. Oxford: Oxford University Press; 2014. p. 415–432.
27. Yassa HA, Dawood AEWA, Shehata MM, et al. Subchronic toxicity of cannabis leaves on male albino rats. *Human and Experimental Toxicology*. 2010;29(1): 37–47. doi:10.1177/0960327109354312
28. Ulugöl A. Kannabinoidlerin klinikte kullanılışı ve terapötik hedefler. *Türkiye Klinikleri J Pharmacol-Special Topics*. 2018;6(1): 42–50.
29. Pryce G, Baker D. Cannabis and Multiple Sclerosis. In: *Pertwee R (ed.) Handbook of Cannabis*. 1st ed. Oxford: Oxford University Press; 2014. p. 487–501.
30. Robson PJ. Therapeutic potential of cannabinoid medicines. *Drug Testing and Analysis*. 2014;6(1–2): 24–30. doi:10.1002/dta.1529
31. Notcutt W, Langford R, Davies P, et al. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols). *Multiple Sclerosis Journal*. 2012;18(2): 219–228. doi:10.1177/1352458511419700
32. Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols\* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. *European Journal of Neurology*. 2011;18(9): 1122–1131. doi:10.1111/j.1468-1331.2010.03328.x
33. Nielsen S, Germanos R, Weier M, et al. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. *Current Neurology and Neuroscience Reports*. 2018;18(2):8. doi:10.1007/s11910-018-0814-x
34. Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. *Neurology*. 2005;65(6): 812–819.
35. Johnson JR, Burnell-Nugent M, Lossignol D, et al. Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain. *Journal of Pain and Symptom Management*. Elsevier Inc; 2010;39(2): 167–179. doi:10.1016/j.jpainsymman.2009.06.008
36. Blake DR, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. *Rheumatology*. 2006;45(1): 50–52. doi:10.1093/rheumatology/kei183
37. Rock E, Sticht M, Parker L. Effect of Phytocannabinoids on Nausea and Vomiting. In: *Pertwee R (ed.) Handbook of Cannabis*. 1st ed. Oxford: University Press; 2014. p. 436–454.
38. Duran M, Pérez E, Abanades S, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. *British Journal of Clinical Pharmacology*. 2010;70(5): 656–663. doi:10.1111/j.1365-2125.2010.03743.x
39. Karadağ Ç. Kannabinoidlerin santral sinir sistemine etkileri. *Türkiye Klinikleri J Pharmacol-Special Topics*. 2018;6(1): 25–34.
40. Cristino L, Di Marzo V. Established and Emerging Concepts of Cannabinoid Action on Food Intake and their Potential Application to the Treatment of Anorexia and Cachexia. In: *Pertwee R (ed.) Handbook of Cannabis*. 1st ed. Oxford: Oxford University Press; 2014. p. 455–472.

41. Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. *The Lancet Neurology*. 2016;15(3): 270–278. doi:10.1016/S1474-4422(15)00379-8
42. Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. *Translational Psychiatry*. 2012;2(3),e94. doi:10.1038/tp.2012.15
43. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. *JAMA - Journal of the American Medical Association*. 2015;313(24): 2456–2473. doi:10.1001/jama.2015.6358
44. Fernández-Ruiz J, Lago E de, Gómez-Ruiz M, et al. Neurodegenerative Disorders Other Than Multiple Sclerosis. In: Pertwee R (ed.) *Handbook of Cannabis*. 1st ed. Oxford: Oxford University Press; 2014. p. 505–525.
45. Huestis MA. Pharmacokinetics and Metabolism of the Plant Cannabinoids,  $\Delta^9$ -Tetrahydrocannabinol, Cannabidiol and Cannabinol. In: Pertwee RG (ed.) *Cannabinoids*. Springer; 2005. p. 657–690.
46. Cone EJ, Bigelow GE, Herrmann ES, et al. Non-smoker exposure to secondhand cannabis smoke. I. Urine screening and confirmation results. *Journal of Analytical Toxicology*. 2015;39(1): 1–12. doi:10.1093/jat/bku116
47. Özşeker PE. Kannabinoidlerin Toksikolojik Analizi. *Türkiye Klinikleri J Pharmacol-Special Topics*. 2018;6(1): 74–77.
48. United Nations Office on Drugs and Crime (UNODC). *World Drug Report 2017*. [Online] [https://www.unodc.org/wdr2017/field/Booklet\\_1\\_EXSUM.pdf](https://www.unodc.org/wdr2017/field/Booklet_1_EXSUM.pdf)
49. Duman M. Kannabise Pasif Maruziyet. *Türkiye Klinikleri J Pharmacol-Special Topics*. 2018;6(1): 68–73.
50. Özşeker P. Kannabinoidlerin Toksikolojik Analizi. *Türkiye Klinikleri J Pharmacol-Special Topics*. 2018;6(1): 74–77.
51. Goullé J-P, Saussereau E, Lacroix C. Delta-9-tetrahydrocannabinol pharmacokinetics. *Ann Pharm Fr*. 2008;66(4): 232–244.
52. Huestis MA. Human Cannabinoid Pharmacokinetics. *Chemistry & Biodiversity*. 2007;4(8): 1770–1804. doi:10.1002/cbdv.200790152.
53. Aydoğdu M, Akgür SA. Urine drug-testing tampering approaches: Turkish probationers. *Medicine, Science and the Law*. 2020; 1–8. doi:10.1177/0025802420956453
54. Busuttill A, Obafunwa JO, Bulgin S. Passive inhalation of cannabis smoke: a novel defence strategy? *J Clin Forensic Med* 1996;3(2):99- 104.
55. Herrman E, Cone E, Mitchell J, et al. Non-Smoker Exposure to Secondhand Cannabis Smoke II: Effect of Room Ventilation on the Physiological, Subjective, and Behavioral/Cognitive Effects. *Drug Alcohol Depend*. 2015;1(151): 194–202. doi:10.1016/j.drugalcdep.2015.03.019.Non-Smoker
56. Bostancı Demirci H, Acar S, Akgür SA. Kannabis Yasal, Ya Sonra.... *The Bulletin of Legal Medicine*. 2020;25(1): 51–58. doi:10.17986/blm.2020.v25i1.1366
57. Aldemir E, Döğ er R, Aydoğ du M, et al. Cannabis, medical use and related policies reflections on society. *Klinik Psikiyatri*. 2020;23: 204-213. doi:DOI: 1 0.5505/kpd.201 9.46547
58. Tubim. *Turkey Drug Report 2017*. [Online] 2017. <http://www.narkotik.pol.tr/TUBIM/Documents/TURKIYE UYUSTURUCU RAPORU 2017.pdf>
59. Parker H, Williams L, Aldridge J. The normalisation of ‘sensible’ recreational drug use: Further evidence from the North West Longitudinal Study. *Drugs and Popular Culture: Drugs, Media and Identity in Contemporary Society*. 2002;36(4): 74–95. doi:10.4324/9781843926016